Biohaven Q2 net loss narrows to $137.3M; advances Graves, epilepsy, oncology pipeline

Biohaven Ltd.

2026-Q2 EPS reported -$1.80

Net loss $137.3M ($0.91/share) vs $198.1M ($1.94/share) in Q2 2025; non-GAAP loss $118.1M ($0.78/share).
Cash, equivalents, marketable securities and restricted cash totaled ~$270.5M as of June 30, 2026.
BHV-1300 Phase 3 in Graves' initiated; Phase 1b showed >80% mean reduction of pathogenic TSHR-IgG1 by week 12.
Opakalim RISE3 topline expected 2H 2026; IGE study showed median time to second seizure 141 vs 47 days placebo.
New clinical supply agreement with Regeneron to evaluate BHV-1530 ADC in combination with Libtayo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.